Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc. (Nasdaq: CRMD), also referred to as CorMedix Therapeutics in recent announcements, generates frequent news as a biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases. Its updates cover commercial performance, clinical development, corporate transactions, and capital markets activity, giving investors and healthcare professionals multiple angles from which to follow the company.
News about CorMedix often highlights the commercial rollout and utilization of DefenCath, an antimicrobial catheter lock solution approved to reduce catheter-related bloodstream infections in certain adult hemodialysis patients using central venous catheters. Press releases have discussed real-world evidence studies with outpatient dialysis organizations, including reductions in infection rates and hospitalizations, as well as recognition such as an Innovative Technology designation from Vizient.
Following its acquisition of Melinta Therapeutics LLC, CorMedix news also covers a broader anti-infective portfolio, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, along with TOPROL-XL. Investors can expect updates on sales trends, integration progress, and synergy capture related to this transaction. Clinical news includes milestones in the Phase III ReSPECT study of REZZAYO for prophylaxis of invasive fungal disease in allogeneic blood and marrow transplant patients, as well as studies of DefenCath in Total Parenteral Nutrition and pediatric hemodialysis populations.
Regulatory and financial announcements are another important category, such as quarterly and annual results, revenue guidance changes, equity and debt financings, and SEC filings describing material events. Strategic items, including CorMedix’s investment in Talphera and associated board representation and negotiation rights, also appear in the company’s news flow. For investors tracking CRMD, this news page provides a centralized view of earnings releases, clinical data readouts, product designations, conference presentations, and governance updates.
CorMedix Inc. (Nasdaq: CRMD) reported its Q1 2021 financial results, showing a net loss of $7.2 million, or $0.20 per share, compared to $5.6 million, or $0.21 per share, in Q1 2020. Operating expenses rose by 29% to $7.2 million, primarily due to a 45% increase in SG&A expenses. The company raised approximately $41.5 million through equity financing and has cash reserves of $81.2 million as of March 31, 2021. CEO Khoso Baluch expressed confidence in advancing their antimicrobial solution, DefenCath, through regulatory approval despite ongoing FDA requirements.
CorMedix Inc. appoints Thomas Nusbickel as Chief Commercial Officer to lead the commercial strategy for DefenCath, an antimicrobial catheter lock solution aimed at reducing catheter-related bloodstream infections (CRBSI) in hemodialysis patients. Nusbickel's extensive experience includes leadership roles in renal product commercialization at Coherus Biosciences and Opko, as well as over two decades at Amgen. This strategic hire comes as CorMedix prepares for the FDA review of DefenCath, which has Fast Track designation and potential marketing exclusivity.
CorMedix announced it will report its Q1 2021 financial results on May 13, after the market close, followed by a conference call at 4:30 PM ET. The company is focused on developing its lead product, DefenCath, designed to prevent bloodstream infections in hemodialysis patients. DefenCath is recognized as a Fast Track product by the FDA, with additional marketing exclusivity provided by its QIDP designation. The company also aims to expand the use of DefenCath and leverage its taurolidine technology for other antimicrobial devices.
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical firm, announced participation in the 7th Annual Truist Securities Life Sciences Summit on May 4-5, 2021. The company focuses on developing products for infectious and inflammatory diseases, notably DefenCath™, an antibacterial solution aimed at preventing bloodstream infections in hemodialysis patients. DefenCath has received Fast Track and QIDP designations from the FDA, providing potential marketing exclusivity. After a Complete Response Letter from the FDA regarding manufacturing deficiencies, CorMedix plans to further develop DefenCath for oncology patients and explore taurolidine technology in their pipeline.
CorMedix Inc. (Nasdaq: CRMD) announced its meeting with the FDA to discuss the resolutions for deficiencies identified in the Complete Response Letter for the NDA of DefenCath™, a taurolidine/heparin catheter lock solution. A protocol for the manual extraction study has been agreed upon, and CorMedix aims to meet FDA requirements in the coming weeks. The timely resubmission of the NDA hinges on the completion of corrective actions prior to that submission. CorMedix is committed to resolving the noted deficiencies to facilitate the FDA's review process.
CorMedix Inc. (Nasdaq: CRMD) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference, scheduled from April 12 – 15, 2021. The presentation will take place on April 14 at 4:30 pm Eastern Time. The company's lead product, DefenCath™, is designed to prevent bloodstream infections in hemodialysis patients. It has received FDA's Fast Track designation and Qualified Infectious Disease Product status, granting it extended marketing exclusivity. Visit cormedix.com for more information.
CorMedix Inc. (Nasdaq: CRMD) announced its financial results for Q4 and full-year 2020, reporting a net loss of $6.1 million in Q4 and $22.0 million for the year. Operating expenses rose 30% to $27.3 million, driven by increased R&D and SG&A expenses. The FDA rejected the NDA for DefenCath, citing issues at the manufacturing facility. Despite this setback, CorMedix plans to address FDA concerns and remains optimistic about DefenCath's potential. The company has $46.3 million in cash, expecting sufficient resources into H2 2022. A conference call is scheduled for March 30, 2021.
CorMedix Inc. (NASDAQ: CRMD) will report its fourth quarter and year-end financial results for 2020 on March 30, 2021, after market close. A corporate update conference call is scheduled for the same day at 4:30 PM ET. The company focuses on developing DefenCath™, an antibacterial and antifungal solution aimed at preventing bloodstream infections in chronic hemodialysis patients. DefenCath has received Fast Track designation from the FDA, which provides extended marketing exclusivity following NDA approval. Updates regarding manufacturing deficiencies are anticipated.
CorMedix Inc. (NASDAQ: CRMD) has received approval from the New Jersey Economic Development Authority to transfer $1.3 million in net operating loss (NOL) tax benefits to an unrelated profitable corporation. This initiative, part of the New Jersey Technology Business Tax Certificate Transfer program, is anticipated to yield $1.3 million in cash proceeds by Q2 2020. CEO Khoso Baluch highlighted that this funding supports the advancement of their lead product, DefenCath, towards a U.S. market launch, focusing on preventing bloodstream infections in chronic hemodialysis patients.
CorMedix (NASDAQ: CRMD) has signed a new three-year employment agreement with Liz Masson-Hurlburt, Executive VP and Head of Clinical Operations, running until March 2024. This appointment comes as the company pursues FDA approval for its product, DefenCath, aimed at preventing infections linked to hemodialysis. Masson-Hurlburt's leadership has been pivotal in successfully completing the LOCK-IT 100 clinical study. CorMedix is also expanding DefenCath's applications into oncology and total parenteral nutrition. The FDA has designated DefenCath as Fast Track and a Qualified Infectious Disease Product.